Wedbush Boosts Earnings Estimates for Compass Therapeutics

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Equities researchers at Wedbush raised their FY2024 earnings per share (EPS) estimates for Compass Therapeutics in a report issued on Tuesday, November 12th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.32) per share for the year, up from their prior forecast of ($0.39). Wedbush currently has a “Outperform” rating and a $8.00 target price on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.42) per share. Wedbush also issued estimates for Compass Therapeutics’ Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.28) EPS, FY2026 earnings at $0.31 EPS and FY2028 earnings at $1.76 EPS.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03.

CMPX has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Monday, November 11th. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Monday, September 16th. Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday. Finally, Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $5.00 to $4.00 in a research note on Friday. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Compass Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $6.75.

Compass Therapeutics Trading Down 13.2 %

NASDAQ:CMPX opened at $1.38 on Friday. The company has a market cap of $189.87 million, a P/E ratio of -3.73 and a beta of 0.92. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34. The company’s 50-day moving average price is $1.75 and its 200-day moving average price is $1.42.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CMPX. Vanguard Group Inc. increased its holdings in shares of Compass Therapeutics by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock worth $8,221,000 after buying an additional 71,008 shares during the last quarter. Opaleye Management Inc. purchased a new position in Compass Therapeutics in the first quarter worth approximately $6,277,000. Geode Capital Management LLC increased its stake in Compass Therapeutics by 0.8% during the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after acquiring an additional 19,095 shares during the last quarter. CM Management LLC raised its position in Compass Therapeutics by 148.0% in the first quarter. CM Management LLC now owns 310,000 shares of the company’s stock valued at $614,000 after purchasing an additional 185,000 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in shares of Compass Therapeutics by 12.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock valued at $284,000 after purchasing an additional 31,433 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.